Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
News|Articles|June 26, 2026
Previewing women's health regulatory updates and conferences in the 2nd half of 2026
Author(s)Contemporary OB/GYN Staff
Fact checked by: Joshua Fitch, Senior Editor
A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.
Advertisement
Advertisement
We're officially at the halfway point of the year, and the back half is shaping up to be just as active as the first for women's health. Below, the Contemporary OB/GYN team looks ahead to a pending FDA decision in the contraception space, along with the leading medical society meetings on the calendar for the remainder of 2026.
Related to this article
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.
Seventy-one percent of women miss their first perimenopausal symptom because anxiety, brain fog, and mood changes precede hot flashes—and most attribute them to stress, per the Bonafide 2026 State of Menopause Survey.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Advertisement
Advertisement